How can iron deficiency be explained in primary polycythemia (polycythemia vera)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Iron Deficiency in Polycythemia Vera: Mechanisms and Clinical Significance

Iron deficiency in polycythemia vera (PV) occurs due to the massive consumption of iron by the hyperproliferative erythroid clone, which depletes body iron stores despite the paradoxical presence of elevated red blood cell mass. This creates a physiological disconnect where patients simultaneously have too many red cells yet insufficient iron to sustain ongoing erythropoiesis 1.

Primary Mechanisms

The iron deficiency in PV results from several interconnected pathways:

Increased Iron Consumption

The JAK2-mutated erythroid clone drives autonomous, uncontrolled red blood cell production that consumes iron at rates far exceeding normal erythropoiesis. This hyperproliferative state creates a functional iron deficiency where iron is rapidly incorporated into hemoglobin, depleting circulating and storage iron pools 1.

Dysregulated Hepcidin Signaling

PV patients demonstrate inappropriately low hepcidin levels relative to their iron-deficient state 1, 2. Normally, iron deficiency suppresses hepcidin to enhance iron absorption and mobilization. However, in PV:

  • The erythroid hyperplasia produces excessive erythroferrone, which suppresses hepcidin
  • Despite low serum ferritin, hepcidin remains insufficiently suppressed to correct the iron deficiency
  • This suggests hepcidin regulation is fundamentally disordered in PV pathobiology 1
  • Chronic inflammation in PV may partially counteract hepcidin suppression, though the relatively low ferritin levels indicate inflammation is not the dominant factor 1

Therapeutic Phlebotomy

Phlebotomy, the cornerstone treatment for maintaining hematocrit <45% in PV, directly removes iron-containing red cells and significantly exacerbates iron deficiency 3, 1. Each phlebotomy removes approximately 200-250 mg of iron.

Additional Contributing Factors

  • Chronic gastrointestinal bleeding (from aspirin therapy or disease-related factors)
  • Potential defects in iron absorption (not fully elucidated)
  • Aberrant hypoxia sensing and signaling pathways 1

Clinical Prevalence and Diagnostic Utility

Iron deficiency occurs in approximately 53% of PV patients, compared to only 1.32% in secondary polycythemia 4. This striking difference makes iron deficiency a highly specific marker:

  • Sensitivity: 52.63%
  • Specificity: 100% for distinguishing PV from secondary polycythemia 4

The presence of iron deficiency in a patient with polycythemia should strongly raise suspicion for PV rather than secondary causes 4.

Clinical Consequences

Iron deficiency in PV contributes to significant symptom burden beyond hematologic parameters:

  • Fatigue and cognitive impairment
  • Restless leg syndrome
  • Headache and dizziness 5, 1

Importantly, iron-deficient red cells demonstrate reduced deformability and increased fragility 6. This altered membrane rheology may:

  • Contribute to shortened red cell survival
  • Potentially increase thrombotic risk, as thrombotic events appear more frequent with depleted iron stores 6
  • Cause paradoxical hyperviscosity despite lower hemoglobin levels

Diagnostic Considerations

Per WHO guidelines, hemoglobin levels are expected to be lower in the presence of iron deficiency, which confounds accurate interpretation of diagnostic criteria 3. The guidelines specify:

  • For research or clinical trials, formal PV diagnosis requires demonstrating WHO criteria are met after iron replacement
  • In routine clinical practice, clinicians should not be prevented from making a working diagnosis of PV in the presence of iron deficiency, even if WHO hemoglobin/hematocrit thresholds are not met 3

This pragmatic approach recognizes that iron deficiency may mask the full erythrocytotic potential of PV.

Management Implications

Cytoreductive therapy (hydroxyurea, ruxolitinib, ropeginterferon) works more effectively to reverse PV-associated symptoms in iron-deficient patients compared to iron-replete patients 1. This paradoxical observation suggests:

  • Iron deficiency may partially limit the erythrocytotic drive
  • Cytoreduction combined with iron-restricted erythropoiesis provides additive disease control

Emerging Therapeutic Approaches

Novel strategies targeting iron metabolism are under investigation 5, 7:

  • Hepcidin mimetics to restrict iron availability to the erythroid clone
  • Ferroportin inhibitors to limit iron mobilization
  • These approaches aim to improve quality of life and potentially reduce cytoreductive therapy needs in low-risk patients

Critical Caveat

Iron supplementation in PV is generally contraindicated as it would fuel the hyperproliferative erythroid clone, worsening polycythemia and potentially increasing thrombotic risk. The exception is when iron replacement is needed to confirm PV diagnosis per WHO criteria in research settings 3.

Related Questions

Does a platelet count of 1.2 × 10⁹/L and ferritin >1000 µg/L in a patient with polycythemia rule out primary polycythemia (polycythemia vera)?
Can polycythemia vera exacerbate or accelerate osteoarthritis?
Which blood test should be performed to exclude polycythemia vera?
Should polycythemia vera be considered in a patient with a persistently elevated hematocrit above 58%?
Why does a polycythemia vera patient undergoing regular phlebotomy develop decreased iron saturation, and what is the appropriate management?
Can you compare demographic transition theory with logistic growth and define sensitivity, specificity, and positive predictive value, list antenatal non‑communicable disease services, WHO‑recommended iron‑folic acid supplementation duration, investigations at the antenatal booking visit, signs of rat infestation, the meaning and staff of Community‑Based Health Planning Services (CHPS), benefits of school feeding programs, social implications of teenage pregnancy, diseases excluded from NHIS pre‑employment assessment, components of periodic workplace health assessments, health and economic impacts of festivals, and the services a community medical officer should provide (antenatal care, immunizations, family planning, cohort study)?
For a patient who has adverse reactions to Repatha (alirocumab), ezetimibe, and statins, what other lipid‑lowering treatment options are available?
Can hydroxyzine (Vistaril) cause an increased heart rate (tachycardia)?
Can vitamin C and methenamine be used to prevent recurrent uncomplicated urinary tract infections in a patient with acidic urine?
Can oral micronized progesterone (e.g., Prometrium) be used as a contraceptive pill, or is it only appropriate for luteal-phase support?
What is the most likely diagnosis for a patient presenting with loss of visual field in the left eye?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.